CardioVascular BioTherapeutics, Inc., a development stage company, focuses on the development and marketing of a protein drug for the treatment of coronary artery disease. Its drug candidate, Cardio Vascu-Grow™, which is in Phase I/II FDA clinical trials, facilitates the growth of new blood vessels in the heart and surrounding vascular system. CardioVascular BioTherapeutics was co founded by Daniel C. Montano and Thomas Stegmann in 1998. The company was formerly known as Cardiovascular Genetic Engineering, Inc. and changed its name to Cardiovascular BioTherapeutics, Inc. in February 2004. CardioVascular BioTherapeutics is headquartered in Henderson, Nevada.